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In the labeled form, the Pittsburgh compound B (2-(4′-{N-methyl-[11C]}
methyl-aminophenyl)-6-hydroxy-benzothiazole, [11C]PiB), is used as a biomarker for
positron emission tomography (PET) of brain β-amyloid deposition in Alzheimer’s disease
(AD). The permeability of [11C]PiB in the blood-brain barrier is held to be high but the
permeability-surface area product and extraction fractions in patients or healthy volunteers
are not known. We used PET to determine the clearance associated with the unidrectional
blood-brain transfer of [11C]PiB and the corresponding cerebral blood flow rates in frontal
lobe, whole cerebral cortex, and cerebellum of patients with Alzheimer’s disease and
healthy volunteers. Regional cerebral blood flow rates differed significantly between
the two groups. Thus, regional and whole-brain permeability-surface area products
were identical, in agreement with the observation that numerically, but insignificantly,
unidirectional blood-brain clearances are lower and extraction fractions higher in the
patients. The evidence of unchanged permeability-surface area products in the patients
implies that blood flow changes can be deduced from the unidirectional blood-brain
clearances of 11C PiB in the patients.[ ]
Keywords: Alzheimers disease, blood-brain barrier, cerebral blood flow measurement, permeability-surface area
product, pittsburgh compound B
INTRODUCTION
The amyloid cascade is the leading current explanation of the
etiology of Alzheimer’s disease (AD) (Hardy and Selkoe, 2002;
Jack et al., 2010). The hypothesis holds that amyloid-β (Aβ)
has a primary role in the biochemical, histological, and patho-
logical changes that happen in the brain when AD evolves.
In this process, the deposition of Aβ is considered an early
event, which implies that biomarkers of Aβ may detect the pres-
ence of disease at the earliest stages of onset (McKhann et al.,
2011).
Modification of the amyloid-binding dye thioflavin-T made
non-invasive PET imaging possible with the labeled form of the
Pittsburgh compound B, the tracer [11C]PiB. Although other
tracers currently are under evaluation (Wong et al., 2013),
[11C]PiB is the most extensively examined marker of Aβ in
human studies with PET (Klunk et al., 2004; Price et al., 2005;
Mintun et al., 2006; Lockhart et al., 2007; Ikonomovic et al.,
2008). Compared to cognitively intact controls, AD patients
exhibit greater [11C]PiB retention in areas known to have high
Aβ deposits such as the frontal and parietal cortices, whereas
brain areas relatively unaffected by Aβ pathology, such as the
cerebellum, show equivalently modest [11C]PiB retention (Klunk
et al., 2004; Price et al., 2005; Ikonomovic et al., 2008). However,
the specific transport and binding properties of [11C]PiB remain
uncertain when the tracer passes from the circulation into the
tissue of the brain.
Klunk et al. (2004) compared the brain uptake of [11C]PiB
with the uptake of fluorine-18-labeled fluorodeoxyglucose
([18F]FDG), a marker of glucose consumption in brain of patients
with Alzheimer’s disease. The authors found that [11C]PiB reten-
tion at late times correlated inversely with cerebral glucose
metabolism traced by [18F]FDG. In the brain of patients with Aβ
deposits, compared to patients without Aβ deposits, significant
[11C]PiB retention correlated well with variable levels of amyloid
deposition, as determined by later postmortem analysis (Klunk
et al., 2004). However, at earlier circulation times, Rostomian
et al. (2011) found comparable [11C]PiB and [18F]FDG uptakes in
patients, consistent with substantial initial clearance of [11C]PiB
from brains of patients, as also found in brains of healthy con-
trol subjects studied by Blomqvist et al. (2008). These results
indicate that the phases of initial uptake and subsequent reten-
tion of [11C]PiB differ in human brain, with initial deposit
of [11C]PiB limited by delivery and hence also by cerebral
blood flow, coupled to metabolism, and later retention limited
by binding to tissue components such as Aβ (Forsberg et al.,
2012).
To determine the extent to which the initial uptake of [11C]PiB
is flow-limited, and to convert the clearance to a measure of
permeability, it is necessary to compute the permeability-surface
area products of microvascular transport of [11C]PiB in differ-
ent brain regions, as well as the fractions of extracted [11C]PiB.
To obtain these values, we must know the values of the cerebral
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blood flow (CBF) that delivers [11C]PiB to brain tissue. Here, to
test the hypothesis of initial flow-limited brain uptake of [11C]PiB
in humans, we determined CBF values and [11C]PiB uptake in
five patients with AD, and six age-matched healthy volunteers, by
means of PET.
METHODS
SUBJECTS
Five patients with AD (3 women, 2 men) with an average
age of 64 (SD = 7) years and moderately reduced Mini-mental
State Examination (MMSE) scores of 22–25 volunteered to
complete the tomography. The patients were recruited by the
local Dementia Clinic and screened by an experienced neurol-
ogist for the presence of definite Dementia of Alzheimer’s Type
(DAT). Six healthy age-matched HC volunteers with MMSE
scores in the range of 28–30 with a mean age of 70 (SD = 5)
years served as controls, recruited by public advertisement and
screened with clinical, neurological, and neuropsychological test-
ing including MMSE adapted to Danish (Lolk et al., 2000) to
exclude cognitive impairment. We obtained written informed
consent from all subjects to the protocols approved by the
Regional Science Ethics Committee in accordance with the
Declarations of Helsinki. We previously reported PET results
from the same five patients and from eight healthy volunteers,
including the six healthy volunteers studied here (Rodell et al.,
2012). We were unable to include two of the healthy volun-
teers because arterial samples of [11C]PiB concentration were
unavailable.
POSITRON EMISSION TOMOGRAPHY
Image acquisition
All subjects had positron emission recordings, one or two with
[15O]water and one with [11C]PiB , in the 3D mode of the ECAT
High Resolution Research Tomograph (HRRT, CTI/Siemens,
Knoxville, TN, USA) in a quiet room with the subjects resting in
a supine position with eyes open. The images were reconstructed
with three-dimensional ordinary Poisson ordered subset expecta-
tion maximization (3D-OP-OSEM) point spread function recon-
struction (Varrone et al., 2009), using 10 iterations and 16 subsets
with FWHM at approximately 1.5mm. The reconstructed images
were corrected for random and scatter events, detector efficiency
variations, and dead time. Tissue attenuation scans were per-
formed using a rotating 68Ge source. Dynamic emission record-
ings lasting 3min (21 frames), or 90min (30 frames) were initi-
ated upon bolus intravenous injection of [15O]water (500MBq)
or [11C]PiB (500MBq), respectively. Catheters (Artflon and
Venflon, Becton Dickinson, Swindon, UK) were inserted in the
right radial artery and left cubital vein. For the [15O]water ses-
sions, arterial blood radioactivity was measured every half second
for the duration of the PET scan by an automated blood sam-
pling system (Allogg AB, Mariefred, Sweden), cross-calibrated
with the tomograph, and then corrected for external delay and
dispersion. For the [11C]PiB sessions, arterial blood radioactivity
was measured in blood samples drawn manually for the duration
of the tomography session. For anatomical orientation, high-
resolution T1-weighted MR images were obtained at 1.5 or 3 T
(GE Sigma Systems).
Image registration and segmentation
The summed emission recordings of [15O]water and [11C]PiB
were automatically co-registered to the individual MRI scans
using a 6 parameter affine transformation. Individual MR images
initially were co-registered to a common stereotactic space
(Montreal Neurological Institute) (Collins and Evans, 1997),
using a 12-parameter affine rigid body transformation, and
subsequently non-linearly transformed. After the calculation of
the final PET-Talairach transformation matrix, dynamic emis-
sion recordings were re-sampled into common coordinates.
Regional CBF and PiB permeability measures (see below) were
obtained from parametric PET image maps using standard model
based segmentation (Collins and Evans, 1997) into regions that
included frontal lobe (FL), cerebral cortex (CTX), and cerebellum
gray matter (CERB).
CALCULATION OF CEREBRAL BLOOD FLOW
We quantified the CBF as the water clearance KH2O1 in units
of mL/100 g/min with the linearized two-compartment model
(Blomqvist, 1984) modification of Ohta et al. (1996) and the
Lawson–Hanson non-negative least squares solution to general
least squares functions (Lawson and Hanson, 1974).
CALCULATION OF BLOOD-BRAIN TRANSFER CONSTANTS OF PiB
UPTAKE
Unidirectional blood-brain clearance
We analyzed the uptake of [11C]PiB by means of multilinear
graphical analysis (Gjedde, 1981, 1982; Patlak et al., 1983). From
the time-radioactivity records in arterial blood samples and brain
tissue, we constructed two derived variables, the dependent vari-
able V(T) and the independent variable (T), according to the
principles of the Gjedde-Patlak Plot, as expanded by Gjedde and
Wong (2001). The two variables are the time-dependent apparent
volume of distribution,
V(T) = m(T)
ca(T)
(1)
and the apparent time of accumulation,
(T) =
∫ T
o ca(t) dt
ca(T)
(2)
which are related by the four parameters of the three-
compartment model of irreversible accumulation, the net clear-
ance K, the unidirectional clearance K1, the dynamic volume of
the precursor compartment Vg , and the dynamic volume of the
vascular compartment Vo,
V(T) = K (T) + Vg
(
1 − e−(K1−K) (T)/Vg
)
+ Vo (3)
that for a simple reversible exchange between the vascular com-
partment and a single tissue compartment, for which K =
0 (k3 = 0), reduces to,
V(T) = Vg
(
1 − e−K1(T)/Vg
)
+ Vo (4)
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used here to obtain the estimates of the unidirectional clearance
K1, because the regression of the complete equation (3) yielded
estimates of K that were not significantly different from zero. At
early times ((T) → 0) V(T) approaches the linear relationship
(Gjedde, 1981),
V(T) → K1 (T) + Vo (5)
Permeability and extraction fraction
The values of cerebral blood flow (F), unidirectional clearance
(K1), and permeability-surface area product (PS) are related by
the formula (Crone, 1963, 1965; Gjedde and Christensen, 1984),
K1 = F
(
1 − e−PS/F) (6)
which yields the extraction fraction as the ratio between the
unidirectional clearance and the blood flow,
E = K1/F = 1 − e−PS/F (7)
from which derives the permeability-surface area product,
PS = −F ln(1 − E) (8)
RESULTS
ARTERIAL PLASMA CONCENTRATIONS
We normalized the arterial plasma concentrations of [11C]PiB to
the area under the curve, as shown in Figure 1. The concentra-
tions revealed a triphasic time course, with an initial rapid rise to
a common peak within a minute of administration, an immedi-
ate decline to a plateau at 4min, maintained at about 10% of the
peak activity until the end of sampling at 90min. The plateau rep-
resents metabolites of [11C]PiB, appearing in significant amounts
after about 4min of circulation of the tracer, as shown in Figure 1.
When the arterial samples are corrected for the metabolite frac-
tions determined by Lopresti et al. (2005), the unchanged tracer
[11C]PiB had declined to less than 3% of the peak activity by
10min after the administration, and to 1% by 15min, indicating
that the tracer practically had disappeared from the circulation at
that time.
BRAIN TIME-ACTIVITY CURVES
The time-activity curves of the three brain regions selected for
the two groups of subjects indicate rapid uptake of [11C]PiB,
which peaks at approximately 2min, and subsequent more or
less rapid washout from about 4min onwards, as shown for
the individual subjects in Figure 2, and for the averages in
Figure 3, superimposed on the average arterial concentration
curves.
MULTITIME GRAPHICAL ANALYSIS
The multitime graphical analysis (MTGA) or Gjedde-Patlak plots
according to equations (1) and (2) show the clear effect of the
generation of metabolites of [11C]PiB that do not enter brain
tissue, with rapid reduction of the apparant volume of dis-
tribution of [11C]PiB in brain tissue as a result, as shown in
Figure 4. For this reason, we limited the period of analysis of
blood-brain transfer of [11C]PiB to the period 0–4min, when
the generation of metabolites was negligible. The MTGA plots
for the time periods 0–4min are shown for patients and con-
trol subjects in Figure 5, in which the regression curves are
shown. When analyzed according to equation (4), the regression
yielded consistent estimates of the four parameters of equation
(3), with values of K close to zero, indicating single tissue com-
partment kinetics (k3 ∼= 0) according to equation (4). With the
value of K fixed at zero, the analysis yielded the estimates of
K1,Vg , and Vo, shown in Figure 6, together with the estimated
values of cerebral blood flow in the same regions. While the
regional CBF values differed significantly between the two groups,
the unidirectional clearances numerically varied in the same
direction as the blood flow values but the differences were not
significant.
PERMEABILITY-SURFACE AREA PRODUCTS
We used the estimates of unidirectional clearance and cere-
bral blood flow to calculate the extraction fractions and
permeability-surface area products of [11C]PiB according to
equations (7) and (8), as listed in Table 1 and shown in Figure 6.
The values of the PS-products were lower than the CBF values
FIGURE 1 | The distributions of arterial plasma concentrations
in healthy volunteers (left panel) and patients with
Alzheimer’s disease (right panel), normalized to average Area
Under Curve (AUC). Abscissa: Log10 rescaling of Time
(minutes). Ordinate: Log10 rescaling of average normalized arterial
plasma radioactivity.
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FIGURE 2 | Normalized individual Time-Activity Curves of three
brain regions, Frontal Lobe (FL), Cerebral Cortex (CTX), and
Cerebellum (CERB), in 6 healthy volunteers (upper row), and
5 patients with Alzheimer’s Disease (lower row). Abscissae:
Time (minutes). Ordinates: Normalized brain radioactivity
(kBq/ml).
FIGURE 3 | Average regional brain Time-Activity Curves
superimposed on average arterial concentration curves. Left panel:
Healthy volunteers. Right panel: Patients with Alzheimer’s disease.
Abscissae: Time (minutes, log10 scale). Left ordinates: Average
normalized plasma activity (kBq/ml). Right ordinates: Average normalized
brain activity (kBq/cm3).
and varied among regions, but the regional values did not differ
significantly between the two groups.
DISCUSSION
In previous publications, we determined the variability of cerebral
blood flow rates in patients with Alzheimer’s disease (Rodell et al.,
2012), and we determined the accumulation of tracer [11C]PiB in
regions of the brains of the same patients in relation to cerebral
blood flow, compared to healthy control subjects.
The issue resolved in the present report is the question of
whether [11C]PiB uptake into the brains of these patients and
healthy volunteers during the early phase of blood-brain transfer
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FIGURE 4 | Multitime graphical analysis (MTGA) plots of blood-brain
transfer of [11C]PiB according to Equations (1) and (2). MTGA plots
reveal effect of generation of metabolites that do not enter brain tissue and
disappearance of [11C]PiB from circulation, with rapid reduction of apparent
volume of distribution [11C]PiB in brain after 4 minutes of circulation,
corresponding to 10min in units of normalized time. Left panel: Healthy
volunteers. Right panel: Patients with Alzheimer’s disease. Abscissae:
Normalized time (minutes). Ordinates: Apparent volume of distribution
(ml/cm3).
FIGURE 5 | Individual MTGA or Gjedde-Patlak plots with regression
curves according to Equations (1) and (2) for 6 healthy volunteers (left
panel), and 5 patients with Alzheimer’s disease (right panel).
Abscissae: Exposure or ‘Theta’ (defined in Equation 2) (“normalized”) time
(minutes). Ordinates: Apparent volume of distribution (ml/cm3).
is flow-limited such that the initial uptake of [11C]PiB can be
used reliably as a marker of blood flow. The evidence from
the study supports the claim that [11C]PiB uptake during the
first 4min of circulation is not completely flow-limited, con-
sistent with substantial but not unlimited permeability in the
cerebral vasculature of patients with Alzheimer’s disease and
healthy control subjects. The PS-products were less than the
values of cerebral blood flow, establishing unidirectional extrac-
tion fraction values at 0.63 or less. A tracer with this prop-
erty yields flow values that are lower than the true values, and
the flow fluctuations are attenuated. Thus, the estimated PS-
products may not be sufficiently high to secure unidirectional
clearance rates that always differ significantly when blood flow
rates decline.
The search for tracers with initial flow-limited uptake suffi-
cient to accurately estimate blood flow rates has been ongoing
for a long time. The issue always concerned the duration of the
flow-limited accumulation, and the determination of themoment
when the accumulation effectively turns from flow-limitation to
significant limitation by diffusion, binding, or metabolism. This
transition happens for all tracers, given enough time. The use of
the marker to trace blood flow therefore is limited to the period
before the transition.
The determination of the brain’s microvascular PS-products
rests on the measure of the marker’s initial clearance, here
symbolized by the term K1, as shown in Figure 7, displaying
both the initial idealized clearance, as derived from the actual
uptake of [11C]PiB into the frontal lobe of a healthy volun-
teer. Judging from this graph, [11C]PiB uptake into brain tis-
sue is effectively unidirectional for only a few minutes after
administration the tracer. The accurate determination of this
initial clearance is aided by regression to the measured mono-
exponential approach to a steady-state volume of distribu-
tion.
In previous attempts to obtain blood-brain clearancemeasures
of [11C]PiB, the authors generally concluded that clearances and
hence uptake rates are “high” but values of permeability-surface
areas were not reported (Blomqvist et al., 2008; Rostomian
et al., 2011), although Blomqvist et al. did obtain unidirectional
clearance estimates. Blomqvist et al. (2008) assumed continu-
ous steady-state accumulation of [11C]PiB in brain tissue, for
which there is little evidence. The issue reflects the uncertainty
of the number of compartments of [11C]PiB distribution in
brain tissue that separately and significantly can be identified
kinetically. The present analysis gave no evidence of continuous
steady-state accumulation of [11C]PiB or its labeled metabolites
in brain tissue and instead reflected the kinetics of a single tissue
compartment.
There is no strongly correlated decline of brain energy
metabolism and cerebral blood flow rates in healthy aging
(Aanerud et al., 2012). Neurodegeneration, on the other hand,
such as Alzheimer’s disease, generally presents with declines of
both variables in specific parts of the brain, most likely driven
by the reduced energy turnover in these same parts of the brain
of demented individuals (Johannsen et al., 2000; Rodell et al.,
2012). The unidirectional blood-brain clearance term K1 is an
expression of the unidirectional influx of [11C]PiB and as such is
related to the blood flow rate bymeans of equation (6). Therefore,
we expected to find a correlation between blood flow estimates
and [11C]PiB accumulation in the first tomography frames of
[11C]PiB uptake. This expectation was supported by the inverse
correlation between blood flow and [11C]PiB accumulation in
the last tomography frames, as evidence of the presence of Aβ
plaques in the tissue. Indeed, blood flow and [11C]PiB accu-
mulation at that time were highly correlated (R2 = 0.999; P =
0.021).
To convert estimates of unidirectional clearance to blood flow
values, the extraction fraction must be known, according to
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FIGURE 6 | Average estimates (±SEM) of cerebral blood flow and
unidirectional clearance, and the calculated values of extraction fraction
and permeability-surface area product of [11C]PiB, according to Equations
(7) and (8). Values of CBF exceeded values of PS-products, which in turn
varied among regions, but did not differ significantly between the two groups.
Ordinates: Units of flow (ml g−1 min−1 ) and extraction percentage (%).
Table 1 | Average estimates (±SEM) of unidirectional blood-brain clearance (K1), extraction percentage (E ), and permeability-surface area
product (PS) in regions of brain of healthy control subjects (HC) and patients with Alzheimer’s disease (AD).
Variable Unit Frontal lobe Cortex Cerebellum
HC AD P HC AD P HC AD P
(n = 6) (n = 5) (n = 6) (n = 5) (n = 6) (n = 5)
F ml hg−1 min−1 54 ± 2 43 ± 3 0.046 52 ± 2 40 ± 3 0.016 54 ± 2 47 ± 2 0.051
K1 ml hg−1 min−1 28 ± 3 25 ± 2 0.57 24 ± 2 22 ± 2 0.67 27 ± 2 26 ± 2 0.84
E % 51 ± 4 59 ± 5 0.14 47 ± 4 55 ± 4 0.094 49 ± 4 56 ± 4 0.99
PS ml hg−1 min−1 40 ± 5 40 ± 4 1.0 34 ± 4 33 ± 4 0.83 38 ± 4 39 ± 4 0.72
P-values indicate probability of insignificant difference, with correction for multiple comparisons.
FIGURE 7 | Idealized clearance and actual uptake of [11C]PiB into
frontal lobe of healthy volunteer. Determination of brain microvascular
Permeability-Surface Area products (PS) rests on measure of initial
blood-brain transfer, or clearance, symbolized by term K1. Abscissa:
Normalized time ‘Theta’ (minutes) as defined in Equation 2. Ordinate:
Apparent volume of distribution (ml/cm3). Note that [11C]PiB uptake into brain
tissue is partially flow-limited for only a few moments after administration.
the equation, F = K1/E. In the present study, the unidirectional
extraction fraction averaged 0.53 for all subjects and regions, but
differed significantly between the patients and the healthy con-
trol subjects. In a companion study, we used the unidirectional
clearance and estimates of PS products to make accurate
predictions of blood flow that correlated well with actual CBF
measures. With an average extraction fraction of 0.53, the values
of blood flow calculated from the unidirectional clearance respec-
tively over- and underestimated the CBF values determined with
labeled water in patients and healthy control subjects and did not
differ significantly on average.
No non-gaseous cerebral blood flow indicator is fully
extracted. Depending on the distribution volume, a quantity of
tracer always remains in the vascular bed, implying that there is
no perfect single compartment modeling that fully describes the
kinetics (Ohta et al., 1992, 1996). The conversion of non-gaseous
tracer uptake therefore depends on the validity of the extraction
fraction used to calculate the blood flow from the unidirectional
blood-brain clearance, determined kinetically or graphically. The
extraction fractions for typical non-gaseous blood flow indica-
tors vary from more than 90% for ethanol, iodoantipyrine, and
butanol, to less than 90% for antipyrine and water (Gjedde et al.,
1975, 1980; Sakurada et al., 1978). The lower the extraction frac-
tion, the more the calculation itself depends on the unknown
blood flow.
Frontiers in Aging Neuroscience www.frontiersin.org November 2013 | Volume 5 | Article 70 | 6
Gjedde et al. Brain uptake of PiB
FIGURE 8 | Relations among clearance (left panel) and extraction
fraction (right panel) estimates and measured cerebral blood flow
values in patients and healthy control subjects according to equations
(6) and (7). Abscissae: Cerebral Blood Flow estimates (ml hg−1 min−1 ).
Ordinate (left panel): Unidirectional [11C]PiB Clearance (ml hg−1 min−1 ).
Ordinate (right panel): Extraction fraction (ratio). Similar regional PS-products
in the two groups explain numerically attenuated and insignificant differences
of unidirectional clearances and extraction fractions.
FIGURE 9 | Estimates of permeability-surface area (PS) products reveal
no relation to measures of cerebral blood flow (CBF) in frontal lobe
(FL), cerebral cortex (CTX), and cerebellum (CERB) of patients and
healthy control subjects. Abscissa: CBF (ml hg−1 min−1 ). Ordinate: PS
products (ml hg−1 min−1 ). Absent correlation is consistent with
incomplete flow-limitation of blood-brain transfer of [11C]PiB.
The relations among the clearance and extraction esti-
mates and the measured flow values are illustrated in Figure 8.
The similar regional PS-products in the two groups explain
the numerically attenuated and hence insignificant differences
between the extraction fractions. Thus, the comparatively low
PS-products are consistent with extraction fractions that do not
change very significantly with changing blood flow rates, as
shown in Figure 9.
The information that can be gleaned from the [11C]PiB uptake
clearly depends on when the uptake is determined. After 10min
of circulation, among the two groups, the retention of [11C]PiB
and its possible metabolites differed significantly for the frontal
lobe and cerebral cortex, but not for the gray matter of the cere-
bellum. In the cortical regions, the uptake of [11C]PiB in the
patients with Alzheimer’s disease exceeded that of the healthy
controls by 40–50%, indicating [11C]PiB retention at this time.
For the cerebellum, the accumulation of [11C]PiB did not dif-
fer between the two groups, as shown in Figure 10. From 1 to
4min of circulation, the brain uptake of [11C]PiB relative to
FIGURE 10 | Accumulation of [11C]PiB in brain tissue in periods of
1–10min and after 10min, in patients in relation to healthy volunteers.
Abscissa: Time (minutes, log10 scale). Ordinate: Fractional difference of
accumulation between patients and control subjects (ratio - 1). From 1 to
5min of circulation, brain uptake of [11C]PiB relative to healthy controls
correlated significantly with the differences of cerebral blood flow
(R2 = 0.999; P = 0.021, data not shown). After 10min of circulation among
patients and healthy controls, relative uptake differed significantly
(P < 0.0005) for frontal lobe and cerebral cortex, but not for gray matter of
cerebellum. In cortical regions, uptake of [11C]PiB in patients exceeded that
of healthy controls by 40–50%, indicating binding-limited [11C]PiB
accumulation in this period. For the cerebellum, the accumulation of
[11C]PiB did not differ between the two groups.
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healthy controls correlated significantly with the differences of
cerebral blood flow (R2 = 0.999; P = 0.021), indicating the par-
tially flow-limited uptake of [11C]PiB during this period shown in
Figure 10.
To claim that a tracer with the properties of [11C]PiB , with
an average extraction fraction of 0.53 ± 0.10 (SD), is useful as
a flow indicator at the very least requires a careful assessment
of the variability of the results and the potential errors that may
arise. In the present study, the correlation coefficient of measured
and calculated flow values was R2 = 0.20 with a significance
of P < 0.01 and a slope of 58% of the line of identity for
a total of 33 comparisons (3 brain regions from 11 subjects
each).
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